Group III: diabetic + liraglutide, the same protocol (HFD + STZ) for induction of diabetes as group II, then rats received liraglutide (0.4 mg/kg/day) subcutaneous injection for 8 weeks (Zhang et al., 2018
PMID: 21795304
Kushima H, Mori Y, Koshibu M, Hiromura M, Kohashi K, Terasaki M, Fukui T, Hirano T
Bs Naples-based Internal Medicine practice today by calling (239) 261-9990.
Supporting gut health, muscle mass, micronutrient sufficiency, inflammation control, and stress resilience enhances outcomes whether or not medication is used
Semaglutide delays gastric emptying and commonly causes gastrointestinal effects